12713-03-0[O]=[Fe][O][Fe]=[O]JEIPFZHSYJVQDO-UHFFFAOYSA-NFerric oxide is an iron oxide.
12713-03-0CHEBI:508195.25 g/cu cm
5.24 g/cm³
5.24
5.24
5.24
Reddish-brown hexagonal crystals
Reddish or blueish-black powder
Steel gray to red hexagonal
Red-brown solid. /Iron oxide dust and fume, as Fe/
A fine, red powder of ferric oxide. /Rouge/
Soluble in acids; insoluble in water, alcohol, ether
Solubility in water: none
Insoluble
Insoluble
Iron 2664 °F
1539 °C
1565 °C
This chemical does not meet GHS hazard criteria for 66.9% (2296 of 3433) of all reports.
Warning
H319 (18.5%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]
P264+P265, P273, P280, P305+P351+P338, P337+P317, P391, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 3433 reports by companies from 44 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Danger
Chemical: Iron oxide (Fe2O3)
Regulation (EC) No 1831/2003 (amended)
Iron oxide (Fe2O3) is listed on the EPA's Chemical Data Reporting (CDR) system. Manufacturers and importers of Iron oxide (Fe2O3) are required to report information about their production and use of this chemical to the EPA under the Toxic Substances Control Act (TSCA). (40 eCFR Part 711)
Status: Active Update: 09-05-2023 https://echa.europa.eu/registration-dossier/-/registered-dossier/15552
iron oxide pigment: Does not have an individual approval but may be used under an appropriate group standard
Iron dust or fume can cause a benign pneumoconiosis called siderosis after exposure to high levels (e.g., 10-700 mg/m3) over a prolonged period of time. Little or no clinical changes have been reported in workers diagnosed with pulmonary siderosis. There is no evidence that iron oxide alone can cause fibrotic changes. Recent animal studies have shown iron oxide in the lung can cause a mild inflammatory response. [ACGIH] See Iron salts, soluble. See Iron oxide (FeO).
Although systemically applied nanoparticles are quickly taken up by phagocytic cells, mainly macrophages, the interactions between engineered nanoparticles and macrophages are still not well defined. ...Therefore ... the uptake of diagnostically used carboxydextran-coated superparamagnetic iron oxide nanoparticles of 60 nm (SPIO) and 20 nm (USPIO) by human macrophages /was analyzed/. By pharmacological and in vitro knockdown approaches, the principal uptake mechanism for both particles was identified as clathrin-mediated, scavenger receptor A-dependent endocytosis... /Iron oxide nanoparticles/
... /It has been/ suggested that ferric oxide serves as a carcinogenic cofactor either by retarding the clearance of inhaled carcinogens or by inducing cytopathological changes which make the cells of the respiratory tract more prone to develop cancer when exposed to carcinogenic substances.
... Proportion of ... iron oxide dust introduced into lungs of experimental animals remained within lungs of tracheo-bronchial lymph nodes throughout ... remaining lifespan. Particles appear to penetate walls of alveoli and respiratory bronchioles and remain in connective tissues of lung within macrophages which form clusters of various sizes ... . /Iron oxide/
Considerable dust may be caught in respirable dust may be caught in resp tract defenses and gotten rid of in sputum, well known to worker because of its rust color.
Normal epithelium prevented deposited Fe2O3 particles from penetrating to connective tissue compartment.
Iron oxide converted to ferritin and hemosiderin in all epithelial cells except mucous cells. Fe content increased over time. Ferritin and hemosiderin, not ferric oxide, noted in connective tissue cells in submocosa.
For more Absorption, Distribution and Excretion (Complete) data for FERRIC OXIDE (9 total), please visit the HSDB record page.
Keine Reaktionsaufzeichnungen unter den aktuellen Filterkriterien.
Wird geladen…
2664 °F
2664 °F
2849 °F
0 mm Hg (approximate)
0 mmHg (approx)
0 mmHg (approx)
0 mmHg (approx)
FCS -> FDA Cumulative Estimated Daily Intake (CEDI)
FCS -> FDA Inventory of Food Contact Substances Listed in 21 CFR
Dry Powder; Other Solid; Dry Powder; Large Crystals; Liquid; Liquid; Dry Powder; Large Crystals; Liquid; Wet Solid; Other Solid; CBI; Large Crystals; Wet Solid; Other Solid; Dry Powder
Reddish-brown solid; Note: Exposure to fume may occur during the arc-welding of iron; [NIOSH] Insoluble in water; [CHEMINFO]
REDDISH BROWN-TO-BLACK CRYSTALS OR POWDER.
Reddish-brown solid.
Reddish-brown solid. [Note: Exposure to fume may occur during the arc-welding of iron.]
A fine, red powder of ferric oxide. [Note: Usually used in cake form or impregnated in paper or cloth.]
Ferric oxide (iron (III) oxide, Fe2O3, CAS Reg. No. 1309-37-1) ... is used as an indirect human food ingredient with no limitation other than current good manufacturing practice. The affirmation of this ingredient as generally recognized as safe (GRAS) as an indirect human food ingredient is based upon the following current good manufacturing practice conditions of use: (1) The ingredient is used as a constituent of paper and paperboard used for food packaging. (2) The ingredient is used at levels not to exceed current good manufacturing practice.
Residues of iron oxide are exempted from the requirement of a tolerance when used in accordance with good agricultural practice as inert (or occasionally active) ingredients in pesticide formulations applied to animals. Use: colorant in pesticide formulations for animal tags. Limit: none.
Noncombustible Solid
Noncombustible Solid
/GUIDE 135: SUBSTANCES - SPONTANEOUSLY COMBUSTIBLE/ Fire or Explosion: Flammable/combustible material. May ignite on contact with moist air or moisture. May burn rapidly with flare-burning effect. Some react vigorously or explosively on contact with water. Some may decompose explosively when heated or involved in a fire. May re-ignite after fire is extinguished. Runoff may create fire or explosion hazard. Containers may explode when heated. /Iron oxide, spent; Iron sponge, spent/
/GUIDE 135: SUBSTANCES - SPONTANEOUSLY COMBUSTIBLE/ Health: Fire will produce irritating, corrosive and/or toxic gases. Inhalation of decomposition products may cause severe injury or death. Contact with substance may cause severe burns to skin and eyes. Runoff from fire control may cause pollution. /Iron oxide, spent; Iron sponge, spent/
/GUIDE 135: SUBSTANCES - SPONTANEOUSLY COMBUSTIBLE/ Public Safety: CALL Emergency Response Telephone Number ... . As an immediate precautionary measure, isolate spill or leak area in all directions for at least 50 meters (150 feet) for liquids and at least 25 meters (75 feet) for solids. Stay upwind. Keep unauthorized personnel away. Keep out of low areas. /Iron oxide, spent; Iron sponge, spent/
/GUIDE 135: SUBSTANCES - SPONTANEOUSLY COMBUSTIBLE/ Protective Clothing: Wear positive pressure self-contained breathing apparatus (SCBA). Wear chemical protective clothing that is specifically recommended by the manufacturer. It may provide little or no thermal protection. Structural firefighters' protective clothing will only provide limited protection. /Iron oxide, spent; Iron sponge, spent/
For more DOT Emergency Guidelines (Complete) data for FERRIC OXIDE (8 total), please visit the HSDB record page.
Fresh air, rest.
First rinse with plenty of water for several minutes (remove contact lenses if easily possible), then refer for medical attention.
(General first aid procedures)
(General first aid procedures)
TIH (Toxic Inhalation Hazard) - Term used to describe gases and volatile liquids that are toxic when inhaled. Some are TIH materials themselves, e.g., chlorine, and some release TIH gases when spilled in water, e.g., chlorosilanes. [ERG 2016].
Persons not wearing protective equipment and clothing should be restricted from areas of releases until cleanup has been completed. If potentially hazardous amounts of iron oxide fume are inadvertantly released, ventilate the area of the release to disperse the fume.
SRP: The most favorable course of action is to use an alternative chemical product with less inherent propensity for occupational harm/injury/toxicity or environmental contamination. Recycle any unused portion of the material for its approved use or return it to the manufacturer or supplier. Ultimate disposal of the chemical must consider: the material's impact on air quality; potential migration in soil or water; effects on animal and plant life; and conformance with environmental and public health regulations.
SRP: Local exhaust ventilation should be applied wherever there is an incidence of point source emissions or dispersion of regulated contaminants in the work area. Ventilation control of the contaminant as close to its point of generation is both the most economical and safest method to minimize personnel exposure to airborne contaminants. Ensure that the local ventilation moves the contaminant away from the worker.
Residues of iron oxide are exempted from the requirement of a tolerance when used in accordance with good agricultural practice as inert (or occasionally active) ingredients in pesticide formulations applied to animals. Use: colorant in pesticide formulations for animal tags. Limit: none.
The concurrent administration of a cocarcinogenic carrier particle such as ferric oxide (Fe2O3) and the polycyclic aromatic hydrocarbon lung carcinogen benzo(a)pyrene (BaP) results in a decreased latency and an increased incidence in the production of lung tumors in hamsters compared to the administration of BaP alone. The pulmonary alveolar macrophage (AM), the primary lung defense cell, has been shown to endocytize BaP, metabolize BaP to a more biologically active form, and then release the metabolites. Therefore, a study was undertaken to determine in a dose-response manner the effect of AM phagocytosis of a carrier particle (Fe2O3) on the metabolism of a carcinogen (BaP) and on the production of reactive oxygen. The AM were lavaged from hamsters and cultured in suspension (2.5 x 10+6 cells/vial) with BaP (62.5 nmol, 14C labeled) alone or adsorbed onto 0.5, 1.0, or 2.0 mg Fe2O3 in the presence of cytochrome c. Following separate ethyl acetate extractions of the AM and medium, the metabolites were isolated by high-performance liquid chromatography (HPLC) and quantified by liquid scintillation spectrometry. The production of superoxide anions was monitored by the reduction of cytochrome c. Concurrent exposure of AM to BaP-coated Fe2O3 resulted in a significant increase in the amount of BaP metabolites and superoxide anions produced with dose of Fe2O3. The following metabolites were identified in both the medium and the AM: 9,10-dihydrodiol, 7,8-dihydrodiol, 4,5-dihydrodiol, 9-hydroxy, 3-hydroxy, and 3,6-quinone. In general, the 7,8-dihydrodiol, which is considered to be the precursor of the ultimate carcinogenic metabolite of BaP, and superoxide anions, which have been shown to produce localized lipid peroxidation and edema in vivo, were significantly enhanced (p = .05, Duncan's multiple comparison test) in AM exposed to all doses of Fe2O3 when compared to AM exposed to BaP alone. This Fe2O3 dose-related enhancement of superoxide anion production is indicative of increased endocytic capacity resulting in a greater amount of total metabolites being produced, in particular, the dihydrodiols of BaP, which are considered to be products of the active metabolic pathway of BaP.
The association of small quantities of ferric oxide with benzo(a)pyrene (BaP) appears to increase in vivo the toxic effect of BaP. The effect of Fe2O3 may be mediated by the recruitment of alveolar macrophages. These cells would contribute to the production of toxic and carcinogenic BaP metabolites and would stimulate development of tumors by producing cellular mediators of inflammation. In order to understand the mechanism of the synergic effect, ... male Sprague Dawley rats 3 weeks of age /were instilled/ with a single dose: Fe2O3 (3 mg) or BaP (3 mg)/combination Fe2O3-BaP (3 mg-3 mg) in 200 microliters of physiological saline solution. Control group of identical size (treated with physiological saline solutions and untreated) were used for this study. Animals were sacrificed 48 hours after instillation and a bronchoalveolar lavage (BAL) was performed. ... An increased malonaldehyde level /was observed/ for rats intoxicated with Fe2O3 (123%), BaP (31%) and Fe2O3 + BaP (56%). The levels of PMN elastase and cathepsin B and L were increased: Fe2O3 (51-58%), BaP (52-27%). This effect was not seen for rats intoxicated by Fe2O3 + BaP. The free alpha(1)-antitrypsin was decreased with the three toxics (Fe2O3: 44%--BaP: 42%--Fe2O3: 41%). The inhibitory capacity of alpha(1)-antitrypsin was lower in groups of rats instilled with toxics.
... The fibrogenic potential of quartz, quartz and ferric oxide administered together, fibrous glass, and hydrated alumina were studied by multiple intratracheal instillation in groups of male Lak:LVG Syrian golden hamsters. Dose-related decreases in survival were evident for the groups instilled with the two highest doses of quartz or quartz and ferric oxide. Instillation of quartz or quartz and ferric oxide induced the greatest pulmonary fibrosis in response to the materials tested. However, the dense fibrous tissue present in the lungs in classical human silicosis and in experimental silicosis of rats was not observed in this study... /Ferric oxide/
The repeated intratracheal instillation, in hamsters, of ferric oxide suspended in normal saline did not give rise to lung tumors. However, given together with benzo(a)pyrene or with systemically administered diethylnitrosamine, an increased yield of lung tumors was obtained. Ferric oxide was thought to be a carcinogenic cofactor, possibly acting by retarding clearance of an inhaled carcinogen or by inducing cytopathological changes that make the cells of the respiratory tract more susceptible to carcinogens.
... Sprague Dawley rats 10 d of age were exposed by inhalation to two different concentrations of ultrafine iron particles (30 or 100 ug/cu m) in combination with soot particles adjusted to maintain a total particle concentration of 250 ug/cu m. Exposure at 10 d and again at 23 d of age was for 6 hr/d for 3 d. Oxidative stress was observed at both Fe concentrations in the form of significant elevations in glutathione disulfide (GSSG) and GSSG/glutathione (GSH) ratio and a reduction in ferric/reducing antioxidant power in bronchoalveolar lavage. A significant decrease in cell viability associated with significant increases in lactate dehydrogenase (LDH) activity, interleukin-1-beta (IL-1beta), and ferritin expression was noted following exposure to particles containing the highest Fe concentration. Iron from these particles was shown to be bioavailable in an in vitro assay using the physiologically relevant chelator, citrate. Data indicate that combined Fe and soot particle exposure induces oxidative injury, cytotoxicity and pro-inflammatory responses in the lungs of neonatal rats. /Iron particles/
respiratory system
Eyes, skin, respiratory system
inhalation
inhalation, skin and/or eye contact
/OTHER TERRESTRIAL SPECIES/ Studies were conducted to determine the effects of a panel of seven nanomaterials (NMs), namely: alpha-alumina, gamma-alumina, precipitated silica; silica fume, calcined silica fume, colloidal antimony pentoxide (Sb(2)O(5)), and superfine amorphous ferric oxide (Fe(2)O(3)), on sediment dwelling invertebrates Chironomus tentans under controlled laboratory conditions. Percentage survival, enzyme activities, growth development, and DNA fragmentation parameters were studied as acute, biochemical, and physiological toxicities of NMs, respectively. Quantitation of catalase and peroxidase enzyme activity demonstrated that toxicant stress of the NMs increased enzyme activity in a concentration dependent fashion across all treatments. The percentage growth length of the test specimens exposed to different NMs was significantly reduced compared to the negative control while only five concentrations were not in the toxic range, namely; Fe(2)O(3) (5 ug/kg); silica fume (5 ug/kg, 50 ug/kg); Sb(2)O(5) (5 ug/kg) and calcined silica fume (5 ug/kg). Genotoxic stress assessed by use of DNA laddering showed complementary findings to the other ecotoxicological endpoints tested in this study-the percentage survival and growth length inhibition. /Amorphous ferric oxide nanoparticles/
Cough.
Redness.
Benign pneumoconiosis with X-ray shadows indistinguishable from fibrotic pneumoconiosis (siderosis)
irritation eyes, skin, respiratory system
/Protect/ from exposure those individuals with pulmonary diseases.
The following medical procedures should be made available to each employee who is exposed to iron oxide fume at potentially hazardous levels: ... A complete history and physical examination ... Examination of the respiratory system should be stressed; 14" X 17" chest roentgenogram; ... FVC and FEV (1 sec). ... The aforementioned medical examinations should be repeated on an annual basis, except that an x-ray is considered necessary only when indicated by the results of pulmonary function testing. /Iron oxide fume/
/HUMAN EXPOSURE STUDIES/ Bronchoalveolar lavage (BAL) was used to sample lung cells and biochemical components in the lung air spaces at various times from 1 to 91 d after intrapulmonary instillation of 2.6 um-diameter iron oxide particles in human subjects. The instillation of particles induced transient acute inflammation during the first day post instillation (PI), characterized by increased numbers of neutrophils and alveolar macrophages as well as increased amounts of protein, lactate dehydrogenase, and interleukin-8 in BAL fluids. This response was subclinical and was resolved within 4 d PI. A similar dose-dependent response was seen in rats 1 d after intratracheal instillation of the same particles. The particles contained small amounts of soluble iron (240 ng/mg) and possessed the capacity to catalyze oxidant generation in vitro. /These/ findings indicate that the acute inflammation after particle exposure may, at least partially, be the result of oxidant generation catalyzed by the presence of residual amounts of ferric ion, ferric hydroxides, or oxyhydroxides associated with the particles... /Iron oxide/
/HUMAN EXPOSURE STUDIES/ ... Some electric arc welders exposed mainly to iron oxide fume showed generalized discrete densities in their chest X-ray films. None of these welders, however, showed any demonstrable clinical disability. /Iron oxide fume/
/HUMAN EXPOSURE STUDIES/ /The authors/ found evidence of siderosis in welders with exposures below 10 mg/cu m, but with probable higher past exposures. /Other investigators/ found exposures to iron oxide fume well over 10 mg/cu m in electric arc and powder-burning operations. Chest X-rays revealed no significant changes in these workers, but relatively few of the workers had long exposure histories and none had worked with iron oxide fume for more than 12 years. /Iron oxide/
/HUMAN EXPOSURE STUDIES/ Ten human subjects were given 5 mg of iron oxide particles (2.6 um) by instillation with the use of a bronchoscope, followed by bronchoalveolar lavage at various time points, to assess the cellular and biochemical response to the instilled particles. Iron oxide particles were made via the hydrolysis and hot dialysis of ferric chloride, which resulted in spherical Fe2O3 particles that contained a soluble iron concentration of 0.036%. A transient acute inflammatory response was observed following instillation based on the appearance of an increased number of neutrophils and alveolar macrophages, and increased amounts of protein, lactate dehydrogenase and interleukin-8 in bronchoalveolar lavage fluid. The residual amount of soluble iron in these particles was shown to catalyze oxidant generation in vitro, which could at least partially explain the observed transient inflammatory response that resolved within 4 days.
For more Human Toxicity Excerpts (Complete) data for FERRIC OXIDE (28 total), please visit the HSDB record page.
Ferric oxide
Group 3: Not classifiable as to its carcinogenicity to humans
Volume 1: (1972) Some Inorganic Substances, Chlorinated Hydrocarbons, Aromatic Amines, N-Nitroso Compounds, and Natural Products
1987
1987
/LABORATORY ANIMALS: Acute Exposure/ ... Fe(2)O(3) nanoparticles with mean diameters of 22 and 280 nm, respectively, were intratracheally instilled to male Sprague Dawley rats at low (0.8 mg/kgbw) and high (20 mg/kgbw) doses. The toxic effects were monitored in the post-instilled 1, 7 and 30 days. ... Fe(2)O(3) nanoparticle exposure could induce oxidative stress in lung. Alveolar macrophage (AM) over-loading of phagocytosed nanoparticle by high dose treatment had occurred, while the non-phagocytosed particles were found entering into alveolar epithelial in day 1 after exposure. Several inflammatory reactions including inflammatory and immune cells increase, clinical pathological changes: follicular hyperplasia, protein effusion, pulmonary capillary vessel hyperaemia and alveolar lipoproteinosis in lung were observed. The sustained burden of particles in AM and epithelium cells has caused lung emphysema and pro-sign of lung fibrosis. At the post-instilled day 30, the typical coagulation parameters, prothrombin time (PT) and activated partial thromboplastin time (APTT) in blood of low dose 22 nm-Fe(2)O(3) treated rats were significantly longer than the controls. We concluded that both of the two-sized Fe(2)O(3) particle intratracheal exposure could induce lung injury. Comparing with the submicron-sized Fe(2)O(3) particle, the nano-sized Fe(2)O(3) particle may increase microvascular permeability and cell lysis in lung epitheliums and disturb blood coagulation parameters significantly.
/LABORATORY ANIMALS: Acute Exposure/ ... When mice were treated with iron oxide nanoparticles (250 ug/kg, 500 ug/kg, and 1mg/kg) by a single intratracheal instillation, the level of intracellular reduced glutathione (GSH) was decreased in the cells of bronchoalveolar lavage (BAL) fluid. The arrest of cell cycles in G1 phase was observed, but S-phase was significantly decreased. The concentrations of pro-inflammatory cytokines (IL-1, TNF-alpha, and IL-6) were dose-dependently increased at day 1 after instillation in the BAL fluid and in the blood. During the experimental period of 28 days, pro-inflammatory cytokines (IL-1, TNF-alpha, and IL-6), Th0 cytokine (IL-2), Th1 type cytokine (IL-12), Th2 type cytokines (IL-4 and IL-5), TGF-beta, and IgE were also elevated. Expressions of many genes related with inflammation or tissue damage such as heat shock protein, matrix metalloproteinase, tissue inhibitors of metalloproteinases, and serum amyloid A were significantly induced. Formation of microgranuloma, which is one of the indicators for chronic inflammatory response, was observed in the alveolar space. In addition, distribution of B cell and CD8+ T cell in blood lymphocytes was increased at day 28. Based on the result, iron oxide nanoparticles may subchronically induce inflammatory responses via oxidative stress in mice by a single intratracheal instillation. /Iron oxide nanoparticles/
/LABORATORY ANIMALS: Acute Exposure/ ... The toxic effects of inhalation exposure to ferric oxide (Fe2O3) ... /were investigated/ in rats. Male Wistar rats were consecutively treated with Fe2O3 at 8.5 mg/kg body weight ... twice daily for 3 days. Content of Fe2O3 ... in tissues, biochemical parameters in serum, and hispathological examinations were analyzed at 12 hr and 36 hr after the 3 day treatment. In the Fe2O3-treated group, iron (Fe) content in liver and lung tissues was significantly increased at 36 hr. ... The levels of serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), total protein (TP), creatine kinase (CK), and lactate dehydrogenase (LDH) ... were significantly decreased compared to the unexposed controls. Histopathological examination showed that /ferric oxide/ nanoparticles caused severe damage in liver and lung tissues. Although this damage progressed in both liver and lung throughout the postexposure period, no significant elevation of serum enzyme activities was observed...
Ferric oxide (iron (III) oxide, Fe2O3, CAS Reg. No. 1309-37-1) ... is used as an indirect human food ingredient with no limitation other than current good manufacturing practice. The affirmation of this ingredient as generally recognized as safe (GRAS) as an indirect human food ingredient is based upon the following current good manufacturing practice conditions of use: (1) The ingredient is used as a constituent of paper and paperboard used for food packaging. (2) The ingredient is used at levels not to exceed current good manufacturing practice.
Residues of iron oxide are exempted from the requirement of a tolerance when used in accordance with good agricultural practice as inert (or occasionally active) ingredients in pesticide formulations applied to animals. Use: colorant in pesticide formulations for animal tags. Limit: none.
Iron oxide is used in pigments, abrasives (jeweler's rouge), and magnetic tapes. Exposure can occur in mining, smelting, grinding steel, polishing, and welding; [ACGIH]
Steel Producing [Category: Industry]
Polishing agent for glass, precious metals, diamonds; in magnets, magnetic tapes; as catalyst; pigment for paper, linoleum, ceramics, glass; paint for ironwork, ship hulls; in electrical resistors and semiconductors; as colloidal solutions as stain for polysaccharides.
As a pigment, mfr of ferrites for electronic uses.
Metallurgy, gas purification, paint and rubber pigment, component of thermite, polishing compounds, mordant, lab reagent, catalyst (p-hydrogen), feed additive, electronic pigments for TV, permanent magnets, memory cores for computers, magnetic tapes.
Used almost exclusively to color decorative concrete; in paints and coatings
(1972) 3.63X10+9 GRAMS (PIGMENTS)
(1975) 7.99X10+9 GRAMS
(1984) 3.90X10+9 g /Iron oxides & Hydroxides/
(1972) 4.24X10+10 G (PIGMENTS)
(1975) 2.52X10+10 G (NATURAL & SYNTHETIC)
(1984) 1.85X10+10 g /Iron oxides & Hydroxides: synthetic, NSPF; synthetic, yellow; synthetic, red; and synthetic, black/
2023: 20,000,000,000 - <25,000,000,000 lb
(1972) 1.55X10+11 G (PIGMENTS)
(1975) 9.48X10+10 G
Production volumes for non-confidential chemicals reported under the Inventory Update Rule. [Table#1316]
Production volume for non-confidential chemicals reported under the 2006 Inventory Update Rule. Chemical: Iron oxide. Aggregated National Production Volume: 50 to < 100 million lbs.
1.36-2.27X10+9 grams of transparent iron oxide pigments for automotive finishes (1973)
44-48% of synthetic iron oxide production is consumed for the print and coatings end use (1981)
END-USE PATTERN: Paints & Coatings, 37%; Building Materials, 22%; Plastics, Inks, Rubber, Glass coloring, 11%; Ferrites & Magnetic uses, 9%; Industrial chemicals, 7%; Animal feeds & Fertilizers, 7%; Misc, 7% (1981) /Natural Iron Oxides/
Alkali precipitation and/or calcination of various iron salts (synthetic); prepared from ores by washing, drying, grinding, blending, and calcining (natural)
Involves the dehydration of synthetic yellow iron oxides in furnaces using controlled temperatures and oxidizing conditions
In Europe ... synthetic red iron oxide is produced by oxidizing the FeO portion of Fe3O4 (black iron oxide) under controlled heating and oxidation conditions
Red iron oxide is formed by atomizing iron pentacarbonyl and burning in an excess of air.
... Prepared synthetically by heating brown iron hydroxide oxide.
Grades: Technical; 99.5% pure, electronic
Ferric oxide, red NF IX--Contains not less than 90% ferric oxide ... Made by heating native ferric oxide or hydroxide at temperature which will yield product of desired color.
Ferric oxide, yellow NF IX-- Contains not less than 97.5% ferric oxide ... Prepared by heating ferrous hydroxide or ferrous carbonate in air at low temperature.
Alpha form occurs in nature as mineral hematite. Gamma form occurs in nature as mineral maghemite; prepared by dehydration of alpha-FeO(OH): Giovanoli, Brutsch, Chimia 28, 188 (1974).
Synthetic iron oxides of high purity are available as single oxides or blends of iron oxides in a range of colors that include yellow, orange, tan, red, maroon, brown and black
Information on 303 consumer products that contain Iron(III) oxide in the following categories is provided:
Information on 13 consumer products that contain Ferric oxide in the following categories is provided:
Food Additives -> COLOUR -> JECFA Functional Classes
Food Additives -> COLOUR -> JECFA Functional Classes
Cosmetics -> Cosmetic colorant
Printing and Related Support Activities
Iron oxide (Fe2O3): ACTIVE
... As source of iron in salt blocks and feeds. ... FDA for many years permitted misleading claims or inferences that it was source of iron ... subsequent biologic availability trials in rats, chicks, cattle, and sheep ... confirmed ... worthlessness as source of iron. ... Used as tracer of feeds ... in nutrition studies.
More than 3-4% of oxide of iron will make sticky superphosphate
Although the supply of natural iron oxide pigments is adequate to satisfy pigment demand, synthetic products have been developed which have better uniformity, strength, and brilliance compared to natural pigments
Usually used in cake form or impregnated in paper or cloth.
/LABORATORY ANIMALS: Acute Exposure/ There was no progressive granulomatous reaction, epithelial hyperplasia, or increase in transforming growth factor-beta1, a fibrogenic cytokine, in rats instilled intratracheally with 20 mg ferric oxide.
For more Non-Human Toxicity Excerpts (Complete) data for FERRIC OXIDE (17 total), please visit the HSDB record page.